Literature DB >> 6302494

Autoimmunity in the Lambert-Eaton myasthenic syndrome.

V A Lennon, E H Lambert, S Whittingham, V Fairbanks.   

Abstract

Sera from 64 patients with the Lambert-Eaton myasthenic syndrome (LES) were tested for evidence of autoimmunity to a variety of tissue antigens. One or more organ-specific autoantibodies (thyroid, gastric, and/or skeletal muscle) were found in 29 patients (45%). Of 46 patients without evidence of tumor, autoantibodies were found in 24 (52%), and of 18 patients with tumor, autoantibodies were found in 5 (28%). In an age-matched group of 40 patients with miscellaneous neurologic diseases, 7 (17%) had one or more organ-specific autoantibodies, and in a control group of 47 patients with myasthenia gravis the combined prevalence of thyroid and gastric antibodies was 47%, comparable to that found in LES patients. The prevalence of non-organ-specific autoantibodies (for example, rheumatoid factor and/or antinuclear antibodies) was not significantly elevated in LES. These data clearly justify consideration of LES without tumor as an organ-specific autoimmune disease. If LES with tumor does prove to have an autoimmune basis, the mechanism may involve an antigen common to cholinergic neurons and oat cell carcinoma, both of which are neuroectoderm derivatives.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6302494

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  19 in total

1.  Abnormalities of autonomic function in the Lambert Eaton myasthenic syndrome.

Authors:  J P Heath; D J Ewing; R E Cull
Journal:  J Neurol Neurosurg Psychiatry       Date:  1988-03       Impact factor: 10.154

Review 2.  Lambert-Eaton myasthenic syndrome.

Authors:  U Seneviratne; R de Silva
Journal:  Postgrad Med J       Date:  1999-09       Impact factor: 2.401

3.  A neuromuscular transmission disorder: combined myasthenia gravis and Lambert-Eaton syndrome in one patient.

Authors:  A Brenna; N Curtò; D D'Urso; F D'Avanzo
Journal:  J Neurol Neurosurg Psychiatry       Date:  1989-05       Impact factor: 10.154

4.  Anesthetic management of a patient suspected of having Lambert-Eaton syndrome due to an unexpected prolongation of vecuronium.

Authors:  Kouichiro Minami; Takeyoshi Sata; Hiroshi Ishimura; Yuko Tomotari; Akio Shigematsu
Journal:  J Anesth       Date:  1994-12       Impact factor: 2.078

5.  Circulating T cell subsets in the Lambert-Eaton myasthenic syndrome.

Authors:  S A Robb; T J Bowley; H N Willcox; J Newsom-Davis
Journal:  J Neurol Neurosurg Psychiatry       Date:  1985-06       Impact factor: 10.154

Review 6.  Lambert-Eaton myasthenic syndrome.

Authors:  J Newsom-Davis
Journal:  Springer Semin Immunopathol       Date:  1985

7.  Passive transfer of Lambert-Eaton syndrome to mice induces dihydropyridine sensitivity of neuromuscular transmission.

Authors:  Michael T Flink; William D Atchison
Journal:  J Physiol       Date:  2002-09-01       Impact factor: 5.182

8.  Neural autoantibody profile of primary achalasia.

Authors:  Robert E Kraichely; Gianrico Farrugia; Sean J Pittock; Donald O Castell; Vanda A Lennon
Journal:  Dig Dis Sci       Date:  2009-06-05       Impact factor: 3.199

Review 9.  Ca2+ channels as targets of neurological disease: Lambert-Eaton Syndrome and other Ca2+ channelopathies.

Authors:  Michael T Flink; William D Atchison
Journal:  J Bioenerg Biomembr       Date:  2003-12       Impact factor: 2.945

10.  Serologic profiles aiding the diagnosis of autoimmune gastrointestinal dysmotility.

Authors:  Radhika Dhamija; K Meng Tan; Sean J Pittock; Amy Foxx-Orenstein; Eduardo Benarroch; Vanda A Lennon
Journal:  Clin Gastroenterol Hepatol       Date:  2008-07-02       Impact factor: 11.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.